Page 830 - ACCCN's Critical Care Nursing

I N D E X 807

nursing advocacy 87–88 organ dysfunction 567–569 external see external pacing
nursing care acute 567t transcutaneous see external pacing
essential see essential nursing care in endocrine system 568 pacing failure 273–274, 274b, 274f
for non-invasive cardiac diagnostic tests 210 adrenal insufficiency 568 PaCO 2 see partial pressure of carbon dioxide
Nursing Council of New Zealand, Code of glycaemia control 569 paediatric end-stage liver disease (PELD) scoring
Conduct for Nurses 79b, 80 hypocalcaemia 569 system 522
nutrition 508–509 steroid therapy 568–569 paediatrics
ARF and 488 in haematologic system 567–569 triage assessment presentations 585
assessment 509 in neurologic system 569 see also children; infants
of indices 509t organisational design, critical care pain 141–145
requirement determination 509 environment 22 assessment of 142–143
burns and 648 organophosphates 604–605 BPS for 142, 143f, 143t
enteral see enteral nutrition orientation 28 chest see chest pain
malnutrition consequences 509 oropharyngeal airways 383 CNPI for 142, 143t
parenteral see parenteral nutrition Guedel 383 CPOT for 142, 143t
support 509–513 oropharyngeal reflexes assessment 434 lung transplantation and 373
NYHA see New York Heart Association orthotopic 787 management of 143–145
functional classification of heart heart transplantation 311, 312f McGill short pain questionnaire 143t
failure liver transplantation 523 non-pharmacological treatment for 144, 144t
NZNO see New Zealand Nurses Organisations OSA see obstructive sleep apnea pathophysiology of 141–142
osmotherapy, for intracranial hypertension pharmacological treatment for 144–145,
management 452–453
145t
O overdose 596–611 post cardiac surgery 302
obese patients complication prevention 598–599, 599t research vignette 150b–151b
care of, essential 117–118 antidotes 599t VAS for 142, 143t
sedation 118 diagnostics 597 verbal numerical scale 142, 143t
VTE prophylaxis 118 physical assessment 597 pain management, palliative care and 172
positioning of 118 previous history 596–597 palliative care 87
objective assessment 787 suspected toxin 597 pain management and 172
obstetric haemorrhage 721–724 time of 597 patient comfort and 172
intra-operative cell salvage for 724 toxin absorption prevention 597–598 pandemic management 33–34
management of 723–724 contact poisons 598 critical care surge plan template 33–34
obstructive sleep apnea (OSA) 336 ingested poisons 597–598 research vignette 34b
occipital cortex 418–419, 422f inhaled poisons 598 surge plan development 33
oedema toxin elimination from blood 598 space 33
cerebral 448 haemodialysis 598 staff 33
conjunctival 108–109 haemoperfusion 598 supplies 33
extracellular (vasogenic) 448 urine alkalinisation 598 PaO 2 see partial pressure of oxygen
intracellular (cytotoxic) 448 see also specific drugs PAOP see pulmonary artery occlusion pressure
MODS and 565 oversensing 274–275, 274f, 275b PAP see pulmonary artery pressure monitoring
pulmonary 334–335, 345 oxygen PAR see patient-at-risk score
pathophysiology of 230, 231f, 334–335 fraction of inspired 392–393, 392t paracetamol poisoning 602
oesophageal balloon tamponade, for liver high-flow nasal vs high-flow face mask, parasympathetic nervous system 431, 432f
dysfunction 520–521 research vignette 375b–376b parenteral nutrition (PN) 513
oesophageal Doppler waveforms 205, 205f maintenance, respiratory failure and 354– see also total parenteral nutrition
off pump coronary artery bypass (OPCAB) 355 paroxysmal supraventricular tachycardia
293–294 toxicity 382, 382b (PSVT) 257
Office for Human Research Protections transport 331 partial brain tissue oxygenation monitoring 439
(OHRP) 82 oxygen consumption (VO 2 ) 331 partial pressure of carbon dioxide (PaCO 2 ) 342,
OHRP see Office for Human Research oxygen delivery (DO 2 ) 331 342t–343t
Protections determinants of 186f partial pressure of oxygen (PaO 2 ) 342, 342t
older child 787 oxygen masks 383 passive exercises 111
oligodendroglia 417, 419t oxygen optimisation compensatory pathophysiology
oliguric renal failure 787 mechanisms 334 of ARDS 363
on-line water 787 oxygen therapy 381–383 of ARF 483–486
OPCAB see off pump coronary artery bypass administration devices for 382 of asthma 365
operational budget 20 complications from 381–382 of burns 644–649
Operational Standard for Ethics Committee, CO 2 narcosis 381–382 of cellular dysfunction 563f
HRCNZ 82 hypoventilation 381–382 of DKA 526, 527f
opt-in donation 746–747, 787 oxygen toxicity 382, 382b of encephalitis 466–467
opt-out donation 787 indications for 381 of GBS 467
oral variable flow devices for 382–383 of ICH 471–472
assessment 109, 109b bag-mask ventilation 383 of myasthenia gravis 469
care, essential 109–110 high-flow nasal cannulae 382 of pain 141–142
hygiene 109–110, 787 low-flow nasal cannulae 382 of pneumonia 357
intubation, vs nasal intubation 385 oxygen masks 383 of pneumothorax 367
organ 787 Venturi systems 383 of preeclampsia 718b
Organ and Tissue Authority 747, 787 oxygen-haemoglobin dissociation curve of respiratory failure 353–354
organ donation 89–91 331–332, 332f secondary to fluid aspiration 613f
ANZICS and 89 of SCA 655
ICU nurse perception on, research of shock 539–541
vignette 760b P of skeletal trauma 629–630
identification of 749–755 P wave 194–195, 194f of TBI 454f, 455–457, 456f, 464t
legislation 747, 748t PAC see pulmonary artery catheter patient advocacy 86
nurses’ attitudes to and knowledge of 90–91 pacing patient dependency 24–26
organ donor care 755–757 cardiac see cardiac pacing patient positioning see positioning patient